NGM Biopharmaceuticals, Inc. announced that it has received $122 million in a round of funding led by returning investor, The Column Group, LLC on July 17, 2024. The transaction included participation from a select group of investors. As a part of transaction, Peter Svennilson of The Column Group, LLC will join the board of directors of the company.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | -1.28% |
|
-.--% | +79.28% |
1st Jan change | Capi. | |
---|---|---|
+79.28% | 129M | |
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |
- Stock Market
- Equities
- NGM Stock
- News NGM Biopharmaceuticals, Inc.
- NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors